28,250 Shares in Guardant Health, Inc. (NASDAQ:GH) Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 28,250 shares of the company's stock, valued at approximately $863,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after acquiring an additional 238,037 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 197,729 shares during the period. Norges Bank acquired a new stake in Guardant Health during the 4th quarter worth approximately $36,438,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Guardant Health by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company's stock worth $31,055,000 after buying an additional 13,395 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Buying and Selling

In other news, CEO Amirali Talasaz sold 106,784 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. This represents a 4.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 107,132 shares of company stock worth $5,249,355 in the last three months. Insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

GH has been the topic of several research reports. Morgan Stanley raised their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Guggenheim reissued a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. UBS Group upped their target price on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Raymond James restated an "outperform" rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Finally, Stifel Nicolaus upped their price target on Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $52.32.

Guardant Health Stock Down 0.7%

GH stock traded down $0.30 during mid-day trading on Tuesday, reaching $41.36. 1,489,633 shares of the stock traded hands, compared to its average volume of 2,211,569. The business has a 50-day moving average of $43.70 and a two-hundred day moving average of $39.24. The firm has a market capitalization of $5.12 billion, a PE ratio of -11.62 and a beta of 1.49. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. Guardant Health's revenue was up 20.8% compared to the same quarter last year. On average, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.